Identification of novel tumor progression genes from SAGE/CAST methods and their diagnostic applications
| Project/Area Number |
21790353
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
SENTANI Kazuhiro Hiroshima University, 大学院・医歯薬学総合研究科, 助教 (30508164)
|
|---|
| Project Period (FY) |
2009 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2010: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2009: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 診断病理学 / 胃癌 / connexin 30 / 腫瘍進展 / 大腸癌 / claudin-18 / CDX2 / 予後 / lamininγ2 |
|---|
| Research Abstract |
Several discrete steps can be discerned in the biological cascades of tumor progression, and several molecules involved in their processes had been reported in gastric cancer (GC). In the present study, we searched for novel genes associated with tumor progression, based on the data of comprehensive gene expression methods. MMP7 and lamininγ2 were associated with tumor progression in GC. In contrast, connexin 30 expression reduced during tumor progression, and is a novel differentiation marker mediating the biological behavior of intestinal phenotype GC. Furthermore, claudin-18 expression correlates with poor survival in patients with CRC and is associated with the gastric phenotype.
|
Report
(3 results)
Research Products
(60 results)
-
-
-
-
-
[Journal Article] Immunohistochemical analysis of colorectal cancer with gastric phenotype : claudin-18 is associated with poor prognosis.2010
Author(s)
Matsuda M, Sentani K, Noguchi T, Hinoi T, Okajima M, Matsusaki K, Sakamoto N, Anami K, Naito Y, Oue N, Yasui W
-
Journal Title
Pathol Int 60(10)
Pages: 673-680
NAID
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Serum olfactomedin (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients.2009
Author(s)
Oue N, Sentani K, Noguchi T, Ohara S, Sakamoto N, Hayashi T, Anami K, Motoshita J, Ito M, Tanaka S, Yoshida K, Yasui W
-
Journal Title
Int J Cancer 125(10)
Pages: 2383-2392
Related Report
Peer Reviewed
-
-
[Journal Article] Immunohistochemical analysis of Reg IV in urogenital organs : Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker.2009
Author(s)
Hayashi T, Matsubara A, Ohara S, Mita K, Hasegawa Y, Usui T, Arihiro K, Norimura S, Sentani K, Oue N, Yasui W
-
Journal Title
Oncol Rep 21(1)
Pages: 95-100
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
